Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

McGill University

$159,665.00

CFTR modulators as a potential new therapeutic paradigm to treat individuals with COPD

EF 2013-14

Résumé
Chronic obstructive pulmonary disease (COPD) is a respiratory disease in which patients suffer from chronic bacterial infection with exaggerated inflammatory responses and a gradual decline in respiratory function. Most COPD cases result from chronic oxidative insults such as tobacco smoke, occupational exposure to fumes, or air pollution. The respiratory symptoms of COPD resemble those seen in cystic fibrosis (CF), which is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated anion channel at the apical surface of epithelial cells. Interestingly, cigarette smoke decreases CFTR function and mucociliary transport in airway bronchial epithelial cells, strong evidence that CFTR dysfunction contributes to the pathophysiology of COPD. In this context, we hypothesize that CFTR modulators will benefit those with acquired CFTR deficiencies such as COPD which have decreased wild-type CFTR activity. During our CF drug discovery program, we spent 3 years identifying small molecules with potential for the treatment of CF, and we are continuing to develop a series of potent CFTR modulators. In this application we propose to "repurpose" these CF compounds for use in COPD since it shares similar features. This approach is strongly supported by recent in vitro studies showing that the CFTR potentiator Ivacaftor (Kalydeco) partially restores mucociliary transport after CFTR inhibition by smoke exposure. From our existing panel of CFTR modulators, the goal of this proposal will be to develop a high quality lead compound which enhances CFTR function in COPD cells, which may offer an excellent opportunity for the development of a new therapeutic which targets airway epithelial cells rather than smooth muscle.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
308201
Name
Hanrahan John W
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
CFTR modulators as a potential new therapeutic paradigm to treat individuals with COPD
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$159,665
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Cftr; Cftr Modulators; Cigarette Smoke Extract; Copd; Novel Copd Drug Development; Primary Human Epithelial Cells
Abstract
Chronic obstructive pulmonary disease (COPD) is a respiratory disease in which patients suffer from chronic bacterial infection with exaggerated inflammatory responses and a gradual decline in respiratory function. Most COPD cases result from chronic oxidative insults such as tobacco smoke, occupational exposure to fumes, or air pollution. The respiratory symptoms of COPD resemble those seen in cystic fibrosis (CF), which is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated anion channel at the apical surface of epithelial cells. Interestingly, cigarette smoke decreases CFTR function and mucociliary transport in airway bronchial epithelial cells, strong evidence that CFTR dysfunction contributes to the pathophysiology of COPD. In this context, we hypothesize that CFTR modulators will benefit those with acquired CFTR deficiencies such as COPD which have decreased wild-type CFTR activity. During our CF drug discovery program, we spent 3 years identifying small molecules with potential for the treatment of CF, and we are continuing to develop a series of potent CFTR modulators. In this application we propose to "repurpose" these CF compounds for use in COPD since it shares similar features. This approach is strongly supported by recent in vitro studies showing that the CFTR potentiator Ivacaftor (Kalydeco) partially restores mucociliary transport after CFTR inhibition by smoke exposure. From our existing panel of CFTR modulators, the goal of this proposal will be to develop a high quality lead compound which enhances CFTR function in COPD cells, which may offer an excellent opportunity for the development of a new therapeutic which targets airway epithelial cells rather than smooth muscle.
Competitiondate
201402
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hanrahan, John W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $159,665~ $0~